BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 162656)

  • 41. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
    Aden U; Jung-Hoffmann C; Kuhl H
    Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipid and biochemical changes after low-dose oral contraception.
    Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
    Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
    Freeman EW; Halbreich U; Grubb GS; Rapkin AJ; Skouby SO; Smith L; Mirkin S; Constantine GD
    Contraception; 2012 May; 85(5):437-45. PubMed ID: 22152588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception.
    Gallo MF; Nanda K; Grimes DA; Schulz KF
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003989. PubMed ID: 15846690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
    Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quartette: an ascending-dose, extended-cycle oral contraceptive.
    Med Lett Drugs Ther; 2013 Jul; 55(1420):54-5. PubMed ID: 23836372
    [No Abstract]   [Full Text] [Related]  

  • 53. Contraception in older woman.
    Volpe A; Silferi M; Genazzani AD; Genazzani AR
    Contraception; 1993 Mar; 47(3):229-39. PubMed ID: 8462314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma lipoproteins and fatty acid composition after "minipill".
    Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M
    Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
    Crona N; Silfverstolpe G; Samsioe G
    Contraception; 1984 Mar; 29(3):261-70. PubMed ID: 6234148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives.
    Sheth A; Jain U; Sharma S; Adatia A; Patankar S; Andolsek L; Pretnar-Darovec A; Belsey MA; Hall PE; Parker RA; Ayeni S; Pinol A; Li Hoi Foo C
    Contraception; 1982 Mar; 25(3):243-52. PubMed ID: 6804162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives.
    Dunson TR; McLaurin VL; Aguayo EL; de Silva P; Calventi V; Gerais AS; Serani RG
    Contraception; 1993 Jun; 47(6):515-25. PubMed ID: 8334888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.
    Contraception; 1980 May; 21(5):445-59. PubMed ID: 7428356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.